LiDia® BSI Test Demonstrates Rapid and Sensitive Identification of Bloodstream Infections Direct from Whole Blood Samples

London, UK and Carlsbad, CA, USA – 18 November 2017 – DNAe, the inventor of semiconductor-based genomic analysis technologies, and the developer of a new, game-changing test for bloodstream infections that can lead to sepsis today announced new data on its test for bloodstream infections, LiDia® BSI. The data demonstrates the ability of the LiDia® BSI closed cartridge-based test to rapidly identify low levels of bacterial and fungal pathogens and resistance markers direct from whole blood, including an example of successful automation. The data were presented as a poster (ID31) at the Association for Molecular Pathology (AMP) Annual Meeting 2017 in Salt Lake City, UT, USA (16th – 18th November).

LiDia® BSI was used to accurately detect the most common pathogens linked to serious bloodstream infections, including the superbug methicillin resistant *S. aureus* (MRSA), less frequent pathogens that are often mistreated empirically, and important resistance markers. The authors of the poster at DNAe confirmed end-to-end functionality of the LiDia® BSI workflow, correctly identifying pathogens and resistance genes at 1 colony-forming unit per ml (CFU/ml). Total turnaround time was less than 5 hours, with current automation of the process expected to reduce the total process time down to less than 3 hours.

The poster presentation includes data on the automation of the LiDia® BSI workflow, used to correctly detect the pathogen, *K. pneumoniae* at 2.5 CFU/ml.

Currently, the standard of care for diagnosis of bloodstream infection is via blood culture, which can take two to six days to produce results. For serious bloodstream infections, which can lead to the life-threatening condition of sepsis, early diagnosis and administration of antimicrobials targeting the causative pathogen is the single most important factor in reducing mortality and morbidity. Reducing time to diagnosis from days to hours therefore has potentially lifesaving implications. On track for CE marking in 2018, LiDia® BSI will reduce unnecessary prescription of antibiotics by providing actionable results directing targeted treatment in just a few hours, direct from raw blood specimen.

Detection of pathogens in healthy donor blood samples spiked at 1 CFU/ml

LiDia® BSI correctly identified the following pathogens in healthy blood samples individually spiked at 1 CFU/ml: *A. baumannii, K. oxytoca, K. pneumoniae, P. mirabilis, E. faecalis, E. faecium, S. aureus, C. albicans, and C. glabrata*.

The absence of resistance markers in these samples was correctly confirmed in *K. pneumoniae, E. faecalis, E. faecium*, and *S. aureus*. In addition, the presence of both pathogen and resistance marker was confirmed for contrived whole blood specimens with vancomycin-resistant *E. faecalis*, vancomycin-resistant *E. faecium, MRSA*, and *K. pneumoniae* harbouring *blaKPC* – all targets spiked at 1 CFU/ml.

Detection of pathogens in clinical whole blood samples by LiDia® BSI

Clinical specimens of MRSA and methicillin-sensitive *S. aureus* were correctly identified directly from whole blood via detection of *S. aureus* and the presence or absence of *mecA/C*, concordant with blood culture results of the samples.

David Davidson, Chief Scientific Officer at DNAe and author on the poster said, “It’s exciting to be able to clearly demonstrate the ability of LiDia® BSI to detect pathogens and antimicrobial resistance present even at low levels, directly from raw blood samples. We continue to process clinical samples with some representative data points presented at this year’s AMP.”

Professor Chris Toumazou, Founder and Executive Chairman at DNAe and author on the poster said, “We are pleased to share this outstanding dataset including an automated exemplar at low limits of detection. Through the eventual automation of the entire workflow, LiDia® BSI has huge potential to cut down time to diagnosis for patients with bloodstream infection. We look forward to sharing larger datasets from our ongoing clinical testing program.”

Dr Steve Allen, CEO of DNAe Group Holdings, commented: “These data provide evidence of the sensitivity, breadth of pathogen coverage, inclusion of resistance genes, and speed of the LiDia® platform and test offering. Presenting these data at the AMP 2017 Annual Meeting is an important stepping stone as we move swiftly towards commercialization of the LiDia® BSI test. The ability to generate robust data from blood within hours, compared to days, will be transformational for patients with bloodstream infection. The next stage in the development process will be to fully integrate the workflow into the cartridge-based test to allow the system to deliver clinically actionable results in less than 3 hours.”

—Ends—

About DNAe – www.dnae.com
DNAe is commercializing its pioneering semiconductor DNA sequencing technology for healthcare applications where rapid near-patient live diagnostics is needed to provide actionable information to clinicians, saving lives by enabling the right treatment at the right time.

In January 2015 DNAe acquired nanoMR, Inc. (now DNA Electronics Inc.), a developer of a novel system for rapid isolation of rare cells in the bloodstream. DNAe is developing LiDia®, its sample-to-result genomic analysis platform, combining DNA Electronics Inc.’s Pathogen Capture System with its own portfolio of semiconductor-based genomic technologies, trademarked Genalysis®. The LiDia® range of tests will enable DNA analysis directly on a microchip, providing rapid and accurate results from a user-friendly system.

DNAe’s initial focus is on infectious disease diagnostics, where speed and DNA-specific information can make the difference between life and death. LiDia® launches with the LiDia® Bloodstream Infection (BSI) test, a groundbreaking rapid direct-from-specimen test for bloodstream infections that lead to sepsis. Built into a compact device for use at the point of need, the system will diagnose accurately and rapidly what infection a patient has, providing the clinician with actionable information to help select the appropriate antibiotics to treat the disease.

In October 2016, the Biomedical Advanced Research and Development Authority (BARDA) a division of the Assistant Secretary for Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS) awarded DNAe a contract worth up to $51.9 million to develop Genalysis® for rapid diagnosis in two key applications; antimicrobial resistant infections and pandemic influenza.

A private company, with bases in London, UK and Carlsbad, CA, USA, DNAe has strong financial backing from its investors, including major shareholder Genting Berhad, a Malaysian-based global investor with a growing portfolio of cutting-edge life sciences companies.
Contact Details

DNAe
Dr Steve Allen, Chief Executive Officer, DNAe Group
Tel: +44 (0)20 7036 2100

Instinctif Partners (media relations)
Sue Charles / Ashley Tapp / Alex Bannister
Tel: +44 (0)20 7457 2020
Email: DNAe@instinctif.com